Pharming Group N.V. (PHAR)
Nasdaq: PHAR · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2020
Who owns Pharming Group N.V.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
0
report now, of 0 people on the record since . Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
Morgan Stanley
SCHEDULE 13G/A · filed Apr 7, 2025 · Ordinary Shares / American Depositary Shares · reported falling below 5%
What PHAR reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
BioConnection BV
An investee · associate · invested in, named in the 20-F/A filed Apr 13, 2026
BioConnection Investments B.V.
An investee · associate · invested in, named in the 20-F/A filed Apr 13, 2026
Abliva AB
A company bought · acquisition · owns, named in the 20-F/A filed Apr 13, 2026
13 subsidiaries in 7 countries, from the list filed with the 20-F filed Apr 2, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.